Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IO

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer

Updated results from a phase 3 trial showed the combination treatment reduced the risk of death by 24% versus chemotherapy alone

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

The drug combination offers biliary tract cancer patients a new treatment option

- PMLiVE

AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients

The phase 3 trial results for patients diagnosed with first-line unresectable liver cancer showed a 31% survival rate after three years

- PMLiVE

AZ’s Imfinzi boosts survival in biliary tract cancer

Positive results for Imfimzi plus chemotherapy offer hope for patients with a rare and aggressive gastrointestinal cancer

- PMLiVE

AZ’s Imfinzi combination shows promise in liver cancer

Combining Imfinzi with experimental monoclonal antibody tremelimumab improved overall survival in patients with the most common form of liver cancer

- PMLiVE

AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients

The drug tripled patient survival after three years in the longest-ever follow-up in extensive-stage small cell lung cancer

- PMLiVE

AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China

Continued approval in MET-positive NSCLC is contingent on the completion of a positive confirmatory trial

- PMLiVE

AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU

European Commission approved Tagrisso in this setting based on positive results from the ADAURA phase 3 study

Roche Basel Switzerland

Roche’s Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Interim results from the phase 3 study to be presented at ASCO 2021

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Combination increases complete response rate to 24% compared to chemotherapy alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links